Chordia Therapeutics Inc. (JP:190A) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chordia Therapeutics Inc. has announced that the World Health Organization has given an International Nonproprietary Name, rogocekib, to their CLK inhibitor CTX-712, which is currently undergoing Phase 1/2 clinical trials in the U.S. This development marks a significant step towards the commercialization of CTX-712, a promising cancer therapy.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.